All In Biotech

Drug Trial Radar · NCT03241342

Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence

Double-Blind, Placebo-Controlled, Parallel Design, Phase 2 Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence

Last checked: Nov 19, 2026Latest source record: Mar 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 491 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

491

Actual

Start

Aug 21, 2017

Primary completion

Sep 21, 2018

Study completion Sep 21, 2018

Sponsor

Lead sponsor
GTxIndustry
Sponsor type
Industry
First posted
Aug 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

GTx-024 is an orally bioavailable and tissue-selective nonsteroidal selective androgen receptor modulator (SARM) that has demonstrated androgenic and anabolic activity and is currently being evaluated as a potential treatment for stress urinary incontinence (SUI) in postmenopausal women. Urinary incontinence and pelvic floor disorders are major health problems for women, especially as they age. Pelvic floor muscle relaxation has been found to correlate with lower urinary tract symptoms including SUI. Muscles of the pelvic floor and lower urinary tract are crucial for supporting the pelvic organs and micturition; however, damage to the muscles or lack of hormonal stimulation are thought to contribute to pelvic organ prolapse and urinary incontinence. Although anabolic steroids may increase muscle mass and strength, lack of oral bioavailability and known potential risks have limited their use. Nonsteroidal SARMs have potential to achieve benefits of anabolic steroid therapy (improved muscle mass, cholesterol/triglyceride levels, glucose metabolism, and bone density) with fewer adverse effects, such as hirsutism and acne, in women. Both nonclinical and clinical data suggest that SARMs may provide a new therapeutic option for pelvic floor and lower urinary tract disorders, as both testosterone and its more potent metabolite, dihydrotestosterone, have anabolic effects on muscle.

Conditions

  • Stress Urinary Incontinence

Interventions

  • GTx 024Drug

    Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024.

  • PlaceboDrug

    Placebo study drug is identical in appearance to the GTx-024 study drug and contains polyethylene glycol 400 but not GTx-024.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With a ≥ 50% Reduction From Baseline in the Mean Number of Stress Incontinence Episodes Per Day at Week 12Time frame: 12 Weeks

Locations

62 sites in 1 country. Site status is shown where the registry gives one.

  • Urology Center of Alabama

    Homewood, Alabama

  • Coastal Clinical Research Inc

    Mobile, Alabama

  • Alaska Clinical Research Center

    Anchorage, Alaska

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Urological Associates of Southern Arizona

    Tucson, Arizona

  • Women's Healthcare Research Corporation

    San Diego, California

  • American Institute of Research

    Whittier, California

  • Genitourinary Surgical Consultants

    Denver, Colorado

  • Urology Associates Research

    Englewood, Colorado

  • Women's Health Specialty Care

    Farmington, Connecticut

  • Coastal Connecticut Research, LLC

    New London, Connecticut

  • Bladder Control Center of Connecticut

    Norwalk, Connecticut

  • James A Simon MD PC

    Washington D.C., District of Columbia

  • South Florida Medical Research

    Aventura, Florida

  • Tampa Bay Medical Research Inc

    Clearwater, Florida

  • Midland Florida Clinical Research Center LLC

    DeLand, Florida

  • Precision Clinical Research

    Lauderdale Lakes, Florida

  • Lone Star Research Center

    Miami, Florida

  • Medical Research of Florida

    Miami, Florida

  • Clinical Research Center of Florida

    Pompano Beach, Florida

  • Mount Vernon Clinical Research LLC

    Sandy Springs, Georgia

  • Clinical Research Prime

    Idaho Falls, Idaho

  • Idaho Urologic Institue

    Meridian, Idaho

  • Women's Health Institution of Illinois

    Oak Lawn, Illinois

  • First Urology PSC

    Jeffersonville, Indiana

  • Iowa Clinic

    West Des Moines, Iowa

  • DelRicht Clinical Research, LLC

    New Orleans, Louisiana

  • Regional Urology

    Shreveport, Louisiana

  • Chesapeake Urology Associates PA

    Hanover, Maryland

  • Boston Clinical Trials

    Boston, Massachusetts

  • Bay State clinical Trials

    Watertown, Massachusetts

  • Beyer Research

    Kalamazoo, Michigan

  • William Beaumont Hospital Urology Research

    Royal Oak, Michigan

  • Women's Clinic of Lincoln

    Lincoln, Nebraska

  • Sheldon J Freedman MD Ltd

    Las Vegas, Nevada

  • Premier Urology Group, LL

    Edison, New Jersey

  • Lawrence Obs Gyn clinical Research

    Lawrenceville, New Jersey

  • Delaware Valley Urology

    Mount Laurel, New Jersey

  • Accumed Research Associates

    Garden City, New York

  • Manhattan Medical Research Practice PLLC

    New York, New York

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.